Skip to content

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

Press Releases

Choose Year
Search Press Releases

Found 90 Results

April 3, 2024

Surrozen Publishes Study in ‘Respiratory Research’ Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

April 1, 2024

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

April 1, 2024

Surrozen Announces Safety,Pharmacodynamic and Liver Function Data for SZN-043

January 18, 2024

Surrozen Provides Corporate Update on Clinical Programs

November 8, 2023

Surrozen Provides Third Quarter 2023 Financial Results

August 9, 2023

Surrozen Provides Second Quarter 2023 Financial Results

June 5, 2023

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 10, 2023

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

April 5, 2023

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

March 22, 2023

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

«...2 345 6...»

IR Contact

Email: investorinfo@surrozen.com

Email Alerts Sign-Up

Email

Unsubscribe

Loading...

Company

About
Management
Board of Directors
Scientific Advisors
Contact
Careers

Science

Science
Pipeline
Publications

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Copyright © 2026 Surrozen. All Rights Reserved

Privacy Policy
FCOI Policy
Accessibility

Scroll to Top